Corcept’s Lifyorli Gains Early FDA Approval, Driving 18.5% Stock Jump
Corcept secured FDA approval for its glucocorticoid receptor agonist Lifyorli over three months ahead of its July 11 PDUFA date in platinum-resistant ovarian cancer after 1-3 prior therapies including bevacizumab. The Phase III ROSELLA study showed Lifyorli plus nab-paclitaxel significantly improved progression-free and overall survival, driving an 18.5% stock rise.
1. FDA Approval Details
Corcept received FDA approval for Lifyorli more than three months before its July 11 PDUFA deadline for use in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer in patients who have undergone 1-3 prior therapies including bevacizumab.
2. Phase III ROSELLA Trial Results
The Phase III ROSELLA trial compared Lifyorli plus nab-paclitaxel against nab-paclitaxel alone in refractory platinum-resistant disease, demonstrating statistically significant improvements in both progression-free survival and overall survival metrics.
3. Market Impact and Stock Reaction
Following the approval announcement, Corcept’s shares surged 18.5%, rising from $34.15 to $40.47 in a single trading session as investors anticipated the drug’s upcoming launch alongside nab-paclitaxel.
4. Future Indication Expansion
As the only selective glucocorticoid receptor agonist on the US market, Lifyorli is poised for additional Phase III trials targeting endometrial, cervical, prostate and pancreatic cancers to broaden its therapeutic reach.